Trevi Gets A Clap On The Back For Chronic Cough Data

A Phase IIa trial studying Haduvio for the treatment of refractory chronic cough showed a benefit for patients, opening the door to a broad market and impressing investors.

Key Takeaways

Trevi’s kappa agonist and mu antagonist (KAMA) Haduvio (nalbuphine ER) showed an efficacy benefit in a Phase IIa trial in refractory chronic cough (RCC).
Haduvio succeeded in a large indication where other drugs have failed or shown only a modest benefit.
Analysts said the readout makes Trevi an attractive takeover candidate.

Trevi Therapeutics succeeded in a Phase IIa trial testing the kappa agonist and mu antagonist (KAMA) Haduvio (nalbuphine ER) in refractory chronic cough (RCC), an indication that has thwarted other pharma firms and for which there are no approved therapies

The company is also developing Haduvio in chronic cough associated with idiopathic pulmonary fibrosis (IPF), where it is in Phase IIb, but RCC represents a substantially broader market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Apnimed’s AD109 Could Be A Wake-Up Call For Sleep Apnea Market

19 May 2025

• By Joseph Haas

The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.

‘Unprecedented’ Data Lift AstraZeneca’s Ambitions For Airsupra

19 May 2025

• By Kevin Grogan

The company hopes the drug will become the standard of care rescue treatment in asthma.

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

12 May 2025

• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

02 May 2025

• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

First Blood-Based Test Cleared For Alzheimer’s Boosts Anti-Amyloid Drugs

19 May 2025

• By Mandy Jackson

The US FDA approval of Fujirebio’s Lumipulse should boost access to medicines like Eisai’s Leqembi and Lilly’s Kisunla; the firms are praising patients’ access to earlier diagnoses.